Impaired wound healing in diabetes: the rationale for clinical use of hyaluronic acid plus silver sulfadiazine
This Review Study was published in 2012 in Minerva Medica Journal (IF 2013:1.202) by Italian specialists. The primary objective of this review is to analyze the most recent evidence supporting the clinical use of a formulation containing hyaluronic acid (HA) and silver sulfadiazine (SSD) in the diabetic patient. This formulation has been widely used in cutaneous lesions of various etiology, both acute and chronic.
HA use in the clinical setting is well established, indeed an overall positive effect of HA can be expected in the healing of chronic wound ulcers of various etiologies, burns, and epithelial surgical wounds, no matter the form in which HA is delivered topically. Coupling the considerations regarding HA activity on tissue repair in diabetes with those supporting SSD application in various types of wounds to control microbial proliferation, it appears that simultaneous application of SSD and HA may be a rational choice for the treatment of chronic lesions affecting diabetic patients.